T Jake Liang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10702994/publications.pdf

Version: 2024-02-01

137 papers	20,045 citations	11608 70 h-index	11288 136 g-index
141 all docs	141 docs citations	141 times ranked	18492 citing authors

#	Article	IF	Citations
1	Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nature Medicine, 2005, 11, 791-796.	15.2	2,561
2	Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA. Science, 2014, 343, 1221-1228.	6.0	774
3	Pathogenesis, Natural History, Treatment, and Prevention of Hepatitis C. Annals of Internal Medicine, 2000, 132, 296.	2.0	764
4	Hepatitis B: The virus and disease. Hepatology, 2009, 49, S13-S21.	3.6	739
5	A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology, 2004, 39, 188-196.	3.6	679
6	Impaired Effector Function of Hepatitis C Virus-Specific CD8+ T Cells in Chronic Hepatitis C Virus Infection. Journal of Immunology, 2002, 169, 3447-3458.	0.4	596
7	Management of hepatitis B: Summary of a clinical research workshop. Hepatology, 2007, 45, 1056-1075.	3.6	568
8	Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nature Genetics, 2011, 43, 1131-1138.	9.4	501
9	A Hepatitis B Virus Mutant Associated with an Epidemic of Fulminant Hepatitis. New England Journal of Medicine, 1991, 324, 1705-1709.	13.9	474
10	Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions. Gastroenterology, 2017, 152, 1297-1309.	0.6	442
11	Current and Future Therapies for Hepatitis C Virus Infection. New England Journal of Medicine, 2013, 368, 1907-1917.	13.9	418
12	Systematic Review: The Effect of Preventive Lamivudine on Hepatitis B Reactivation during Chemotherapy. Annals of Internal Medicine, 2008, 148, 519.	2.0	407
13	The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology, 2010, 52, 894-903.	3.6	403
14	Progression of fibrosis in chronic hepatitis C. Gastroenterology, 2003, 124, 97-104.	0.6	368
15	Hepatitis C Virus Structural Proteins Assemble into Viruslike Particles in Insect Cells. Journal of Virology, 1998, 72, 3827-3836.	1.5	345
16	A global scientific strategy to cure hepatitis B. The Lancet Gastroenterology and Hepatology, 2019, 4, 545-558.	3.7	342
17	Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. Hepatology, 2003, 38, 1075-1086.	3.6	340
18	A genome-wide genetic screen for host factors required for hepatitis C virus propagation. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 16410-16415.	3.3	333

#	Article	IF	Citations
19	Long-Term Therapy of Chronic Hepatitis B With Lamivudine. Hepatology, 2000, 32, 828-834.	3.6	326
20	Present and future therapies of hepatitis B: From discovery to cure. Hepatology, 2015, 62, 1893-1908.	3.6	269
21	Natural Killer Cells Are Polarized Toward Cytotoxicity in Chronic Hepatitis C in an Interferon-Alfaâ€“Dependent Manner. Gastroenterology, 2010, 138, 325-335.e2.	0.6	243
22	Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology, 2007, 46, 1548-1563.	3.6	242
23	HCV Infection Induces a Unique Hepatic Innate Immune Response Associated With Robust Production of Type III Interferons. Gastroenterology, 2012, 142, 978-988.	0.6	241
24	The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology, 2007, 46, 424-429.	3.6	227
25	Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function. Gastroenterology, 2015, 149, 190-200.e2.	0.6	222
26	Virologic Monitoring of Hepatitis B Virus Therapy in Clinical Trials and Practice: Recommendations for a Standardized Approach. Gastroenterology, 2008, 134, 405-415.	0.6	215
27	Pathogenesis of hepatitis Câ€”associated hepatocellular carcinoma. Gastroenterology, 2004, 127, S62-S71.	0.6	203
28	17â€Beta Hydroxysteroid Dehydrogenase 13ÂIs a Hepatic Retinol Dehydrogenase Associated With Histological Features of Nonalcoholic Fatty Liver Disease. Hepatology, 2019, 69, 1504-1519.	3.6	200
29	Hepatitis B Virusâ€“Specific and Global T-Cell Dysfunction in Chronic Hepatitis B. Gastroenterology, 2016, 150, 684-695.e5.	0.6	178
30	Hepatitis C virus infection activates an innate pathway involving IKK-Î± in lipogenesis and viral assembly. Nature Medicine, 2013, 19, 722-729.	15.2	167
31	Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 8427-8432.	3.3	157
32	Hepatocyte NAD(P)H oxidases as an endogenous source of reactive oxygen species during hepatitis C virus infection. Hepatology, 2010, 52, 47-59.	3.6	153
33	Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 6753-6758.	3.3	152
34	Robust Production of Infectious Hepatitis C Virus (HCV) from Stably HCV cDNA-Transfected Human Hepatoma Cells. Journal of Virology, 2005, 79, 13963-13973.	1.5	144
35	Current progress in development of hepatitis C virus vaccines. Nature Medicine, 2013, 19, 869-878.	15.2	144
36	Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology, 2011, 53, 32-41.	3.6	140

#	Article	IF	Citations
37	Engrafted human stem cellâ€“derived hepatocytes establish an infectious HCV murine model. Journal of Clinical Investigation, 2014, 124, 4953-4964.	3.9	131
38	Effects of antiviral therapy on the cellular immune response in acute hepatitis C. Hepatology, 2004, 40, 87-97.	3.6	130
39	Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection. Science Translational Medicine, 2015, 7, 282ra49.	5.8	118
40	Hepatitis C virus entry: Molecular biology and clinical implications. Hepatology, 2006, 44, 527-535.	3.6	116
41	Characterization and biological properties of a hepatitis B virus isolated from a patient without hepatitis B virus serologic markers. Hepatology, 1990, 12, 204-212.	3.6	115
42	Interaction of Hepatitis C Virus-Like Particles and Cells: a Model System for Studying Viral Binding and Entry. Journal of Virology, 2002, 76, 9335-9344.	1.5	113
43	A functional SNP of interferon-Î³ gene is important for interferon-Î±-induced and spontaneous recovery from hepatitis C virus infection. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 985-990.	3.3	109
44	The Application and Mechanism of Action of Ribavirin in Therapy of Hepatitis C. Antiviral Chemistry and Chemotherapy, 2012, 23, 1-12.	0.3	109
45	Persistence of hepatitis B viral DNA after serological recovery from hepatitis B virus infection. Hepatology, 1991, 14, 56-63.	3.6	106
46	Immunization with Hepatitis C Virus-Like Particles Induces Humoral and Cellular Immune Responses in Nonhuman Primates. Journal of Virology, 2004, 78, 6995-7003.	1.5	106
47	Mutation Rate of the Hepatitis C Virus NS5B in Patients Undergoing Treatment With Ribavirin Monotherapy. Gastroenterology, 2007, 132, 1757-1766.	0.6	105
48	Hepatitis B Immunoglobulin and Lamivudine Improve Hepatitis Bâ€“Related Outcomes After Liver Transplantation: Meta-Analysis. Clinical Gastroenterology and Hepatology, 2008, 6, 696-700.	2.4	105
49	Human stem cell-derived hepatocytes as a model for hepatitis B virus infection, spreading and virus-host interactions. Journal of Hepatology, 2017, 66, 494-503.	1.8	105
50	An in vitro model of hepatitis C virion production. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 2579-2583.	3.3	104
51	Therapy of Hepatitis C â€” Back to the Future. New England Journal of Medicine, 2014, 370, 2043-2047.	13.9	102
52	Integrative Functional Genomics of Hepatitis C Virus Infection Identifies Host Dependencies in Complete Viral Replication Cycle. PLoS Pathogens, 2014, 10, e1004163.	2.1	101
53	Defective Hepatic Response to Interferon and Activation of Suppressor of Cytokine Signaling 3 in Chronic Hepatitis C. Gastroenterology, 2007, 132, 733-744.	0.6	100
54	Human Monoclonal Antibody to Hepatitis C Virus E1 Glycoprotein That Blocks Virus Attachment and Viral Infectivity. Journal of Virology, 2004, 78, 7257-7263.	1.5	98

#	Article	IF	Citations
55	Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: A longitudinal analysis. Hepatology, 2013, 58, 1548-1557.	3.6	96
56	Direct, Interferon-Independent Activation of the CXCL10 Promoter by NF-ÎºB and Interferon Regulatory Factor 3 during Hepatitis C Virus Infection. Journal of Virology, 2014, 88, 1582-1590.	1.5	96
57	Production of Infectious Hepatitis C Virus of Various Genotypes in Cell Cultures. Journal of Virology, 2007, 81, 4405-4411.	1.5	95
58	Hepatitis C virusâ€“like particles induce virus-specific humoral and cellular immune responses in mice. Hepatology, 2001, 34, 417-423.	3.6	90
59	Changes in Serum Adipokine Levels During Pioglitazone Treatment for Nonalcoholic Steatohepatitis: Relationship to Histological Improvement. Clinical Gastroenterology and Hepatology, 2006, 4, 1048-1052.	2.4	90
60	Hepatitis B virus infection in patients with idiopathic liver disease. Hepatology, 1991, 13, 1044-1051.	3.6	88
61	Uptake and presentation of hepatitis C virus-like particles by human dendritic cells. Blood, 2005, 105, 3605-3614.	0.6	86
62	Development of Direct-acting Antiviral and Host-targeting Agents for Treatment of Hepatitis B Virus Infection. Gastroenterology, 2019, 156, 311-324.	0.6	85
63	The Clearance of Hepatitis C Virus Infection in Chimpanzees May Not Necessarily Correlate with the Appearance of Acquired Immunity. Journal of Virology, 2003, 77, 862-870.	1.5	84
64	Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. Hepatology, 2003, 38, 66-74.	3.6	83
65	Scavenger Receptor Class B Is Required for Hepatitis C Virus Uptake and Cross-Presentation by Human Dendritic Cells. Journal of Virology, 2008, 82, 3466-3479.	1.5	79
66	Amphipathic DNA Polymers Inhibit Hepatitis C Virus Infection by Blocking Viral Entry. Gastroenterology, 2009, 137, 673-681.	0.6	78
67	Naturally Occurring Mutations Define a Novel Function of the Hepatitis B Virus Core Promoter in Core Protein Expression. Journal of Virology, 1998, 72, 6785-6795.	1.5	75
68	Reactivation of Hepatitis B During Immunosuppressive Therapy: Potentially Fatal Yet Preventable. Annals of Internal Medicine, 2012, 156, 743.	2.0	74
69	Hepatic differentiation of human pluripotent stem cells in miniaturized format suitable for high-throughput screen. Stem Cell Research, 2016, 16, 640-650.	0.3	74
70	Antibodies Against Hepatitis C Virusâ€“Like Particles and Viral Clearance in Acute and Chronic Hepatitis C. Hepatology, 2000, 32, 610-617.	3.6	72
71	Structural Features of Envelope Proteins on Hepatitis C Virus-like Particles as Determined by Anti-envelope Monoclonal Antibodies and CD81 Binding. Virology, 2002, 298, 124-132.	1.1	71
72	Inhibition of Hepatitis C Virus-Like Particle Binding to Target Cells by Antiviral Antibodies in Acute and Chronic Hepatitis C. Journal of Virology, 2004, 78, 9030-9040.	1.5	70

#	Article	IF	Citations
73	Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection. Hepatology, 2006, 43, 780-787.	3.6	70
74	Experimental models of hepatitis B and C â€" new insights and progress. Nature Reviews Gastroenterology and Hepatology, 2016, 13, 362-374.	8.2	70
75	Cellular microRNA networks regulate host dependency of hepatitis C virus infection. Nature Communications, 2017, 8, 1789.	5.8	70
76	Vaccine Development for Hepatitis C. Seminars in Liver Disease, 2000, 20, 211-226.	1.8	67
77	Dynamic Interaction of Stress Granules, DDX3X, and IKK-Î± Mediates Multiple Functions in Hepatitis C Virus Infection. Journal of Virology, 2015, 89, 5462-5477.	1.5	67
78	Src Homology 3 Domain of Hepatitis C Virus NS5A Protein Interacts With Bin1 and Is Important for Apoptosis and Infectivity. Gastroenterology, 2006, 130, 794-809.	0.6	62
79	Reactivation of Hepatitis B With Reappearance of Hepatitis B Surface Antigen After Chemotherapy and Immunosuppression. Clinical Gastroenterology and Hepatology, 2009, 7, 1130-1137.	2.4	62
80	X-deficient woodchuck hepatitis virus mutants behave like attenuated viruses and induce protective immunity in vivo. Journal of Clinical Investigation, 2001, 108, 1523-1531.	3.9	57
81	Hepatitis C virus JFH-1 strain infection in chimpanzees is associated with low pathogenicity and emergence of an adaptive mutation. Hepatology, 2008, 48, 732-740.	3.6	56
82	Hepatitis B virus mutations associated with fulminant hepatitis induce apoptosis in primaryTupaiahepatocytes. Hepatology, 2005, 41, 247-256.	3.6	55
83	Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFNÎ±. Gut, 2017, 66, 724-735.	6.1	55
84	Sporadic Reappearance of Minute Amounts of Hepatitis C Virus RNA After Successful Therapy Stimulates Cellular Immune Responses. Gastroenterology, 2011, 140, 676-685.e1.	0.6	52
85	Cryo-electron microscopy and three-dimensional reconstructions of hepatitis C virus particles. Virology, 2007, 367, 126-134.	1.1	51
86	Mouse models for the study of HCV infection and virusâ€"host interactions. Journal of Hepatology, 2008, 49, 134-142.	1.8	51
87	Hepatitis C virus depends on E-cadherin as an entry factor and regulates its expression in epithelial-to-mesenchymal transition. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 7620-7625.	3.3	50
88	Hepatitis C virusâ€"like particles combined with novel adjuvant systems enhance virus-specific immune responses. Hepatology, 2003, 37, 52-59.	3.6	48
89	Current and Future Therapies for Hepatitis C Virus Infection. New England Journal of Medicine, 2013, 369, 679-680.	13.9	45
90	Infection of Hepatocytes With HCV Increases Cell Surface Levels of Heparan Sulfate Proteoglycans, Uptake of Cholesterol and Lipoprotein, and Virus Entry by Up-regulating SMAD6 and SMAD7. Gastroenterology, 2017, 152, 257-270.e7.	0.6	43

#	Article	IF	Citations
91	What is the future of ribavirin therapy for hepatitis C?. Antiviral Research, 2014, 104, 34-39.	1.9	41
92	Placebo in Nonalcoholic Steatohepatitis: Insight Into Natural History and Implications for Future Clinical Trials. Clinical Gastroenterology and Hepatology, 2008, 6, 1243-1248.	2.4	40
93	Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection. Journal of Clinical Investigation, 2020, 130, 3205-3220.	3.9	38
94	Structural proteins of Hepatitis C virus induce interleukin 8 production and apoptosis in human endothelial cells. Journal of General Virology, 2005, 86, 3291-3301.	1.3	37
95	Presence of hepatitis B and C viral genomes in US blood donors as detected by polymerase chain reaction amplification. Journal of Medical Virology, 1994, 42, 151-157.	2.5	36
96	Altered Proteolysis and Global Gene Expression in Hepatitis B Virus X Transgenic Mouse Liver. Journal of Virology, 2006, 80, 1405-1413.	1.5	35
97	Novel Function of CD81 in Controlling Hepatitis C Virus Replication. Journal of Virology, 2010, 84, 3396-3407.	1.5	35
98	Modeling PNPLA3â€Associated NAFLD Using Humanâ€Induced Pluripotent Stem Cells. Hepatology, 2021, 74, 2998-3017.	3.6	35
99	Hepatitis B e Antigen â€" The Dangerous Endgame of Hepatitis B. New England Journal of Medicine, 2002, 347, 208-210.	13.9	31
100	Antiviral and Immunoregulatory Effects of Indoleamine-2,3-Dioxygenase in Hepatitis C Virus Infection. Journal of Innate Immunity, 2015, 7, 530-544.	1.8	31
101	Novel Cell-Based Hepatitis C Virus Infection Assay for Quantitative High-Throughput Screening of Anti-Hepatitis C Virus Compounds. Antimicrobial Agents and Chemotherapy, 2014, 58, 995-1004.	1.4	30
102	Discovery, Optimization, and Characterization of Novel Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection. Journal of Medicinal Chemistry, 2016, 59, 841-853.	2.9	30
103	Monoclonal Antibodies with Broad Specificity for Hepatitis C Virus Hypervariable Region 1 Variants Can Recognize Viral Particles. Journal of Immunology, 2001, 167, 3878-3886.	0.4	29
104	Interferon-gamma inhibits interferon-alpha signalling in hepatic cells: evidence for the involvement of STAT1 induction and hyperexpression of STAT1 in chronic hepatitis C. Biochemical Journal, 2004, 379, 199-208.	1.7	29
105	Ribavirin improves the IFN-Î³ response of natural killer cells to IFN-based therapy of hepatitis C virus infection. Hepatology, 2014, 60, 1160-1169.	3.6	26
106	N-Myc Downstream-Regulated Gene 1 Restricts Hepatitis C Virus Propagation by Regulating Lipid Droplet Biogenesis and Viral Assembly. Journal of Virology, 2018, 92, .	1.5	24
107	High-Throughput Screening, Discovery, and Optimization To Develop a Benzofuran Class of Hepatitis C Virus Inhibitors. ACS Combinatorial Science, 2015, 17, 641-652.	3.8	23
108	Novel Approaches to New Therapies for Hepatitis B Virus Infection. Antiviral Therapy, 2006, 11, 1-15.	0.6	23

#	Article	IF	Citations
109	Controlled Human Infection Model â€" Fast Track to HCV Vaccine?. New England Journal of Medicine, 2021, 385, 1235-1240.	13.9	22
110	Hepatic Transcriptome Analysis of Hepatitis C Virus Infection in Chimpanzees Defines Unique Gene Expression Patterns Associated with Viral Clearance. PLoS ONE, 2008, 3, e3442.	1.1	22
111	In vivo adaptation of hepatitis C virus in chimpanzees for efficient virus production and evasion of apoptosis. Hepatology, 2011, 54, 425-433.	3.6	21
112	Inhibition of Cellular Proteasome Activities Mediates HBX-Independent Hepatitis B Virus Replication In Vivo. Journal of Virology, 2010, 84, 9326-9331.	1.5	20
113	MicroRNA-135a Modulates Hepatitis C Virus Genome Replication through Downregulation of Host Antiviral Factors. Virologica Sinica, 2019, 34, 197-210.	1.2	19
114	Evaluation of antiviral drug synergy in an infectious HCV system. Antiviral Therapy, 2016, 21, 595-603.	0.6	18
115	Chlorcyclizine Inhibits Viral Fusion of Hepatitis C Virus Entry by Directly Targeting HCV Envelope Glycoprotein 1. Cell Chemical Biology, 2020, 27, 780-792.e5.	2.5	18
116	Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle. Journal of Medicinal Chemistry, 2017, 60, 6364-6383.	2.9	12
117	Hepatitis C Virus Infection Induces Hepatic Expression of NF-Î¹B-Inducing Kinase and Lipogenesis by Downregulating miR-122. MBio, 2019, 10, .	1.8	12
118	Cryo-EM study of Hepatitis B virus core antigen capsids decorated with antibodies from a human patient. Journal of Structural Biology, 2012, 177, 145-151.	1.3	11
119	Preclinical Pharmacological Development of Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection. Journal of Infectious Diseases, 2018, 217, 1761-1769.	1.9	11
120	TM6SF2 Promotes Lipidation and Secretion of Hepatitis C Virus in Infected Hepatocytes. Gastroenterology, 2018, 155, 1923-1935.e8.	0.6	11
121	Novel approaches to new therapies for hepatitis B virus infection. Antiviral Therapy, 2006, 11, 1-15.	0.6	10
122	Identification of novel anti-hepatitis C virus agents by a quantitative high throughput screen in a cell-based infection assay. Antiviral Research, 2015, 124, 20-29.	1.9	9
123	HCV RNA in patients with chronic hepatitis C treated with interferon-Î±. Journal of Medical Virology, 1993, 40, 69-75.	2.5	8
124	Shortened Therapy for Hepatitis C Virus Genotype 2 or 3 â€" Is Less More?. New England Journal of Medicine, 2007, 357, 176-178.	13.9	8
125	Vaccination against hepatitis C virus infection: Miles to go before we sleep. Hepatology, 1994, 20, 758-760.	3.6	7
126	Single Strain Isolation Method for Cell Culture-Adapted Hepatitis C Virus by End-Point Dilution and Infection. PLoS ONE, 2014, 9, e98168.	1.1	7

#	Article	IF	Citations
127	Treatment of chronic hepatitis B. Antiviral Therapy, 2007, 12 Suppl 3, H33-41.	0.6	7
128	I Molecular biology of hepatitis C virus. Biomedical Research Reports, 2000, 2, 1-I.	0.3	6
129	The X-Files of hepatitis B. Nature, 2016, 531, 313-314.	13.7	6
130	A randomized, proof-of-concept clinical trial on repurposing chlorcyclizine for the treatment of chronic hepatitis C. Antiviral Research, 2019, 163, 149-155.	1.9	6
131	Impact of host and virus genome variability on HCV replication and response to interferon. Current Opinion in Virology, 2013, 3, 501-507.	2.6	5
132	Discovery and characterization of a novel HCV inhibitor targeting the late stage of HCV life cycle. Antiviral Therapy, 2019, 24, 371-381.	0.6	5
133	Alternative interferons and immunomodulators in the treatment of hepatitis C. Liver International, 2014, 34, 133-138.	1.9	3
134	Border Control in Hepatitis C Virus Infection: Inhibiting Viral Entry. ACS Infectious Diseases, 2015, 1, 416-419.	1.8	2
135	Hepatitis C Virus: From Obscurity to the Lasker. Gastroenterology, 2016, 151, 1052-1053.	0.6	1
136	Natural history of hbeag-negative chronic Hepatitis b. Current Hepatitis Reports, 2006, 5, 27-32.	0.3	0
137	Acute and Chronic Hepatitis B and D. , 1998, , 121-129.		0